Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIDDO: Once-Daily Tacrolimus in AYA Kidney Transplant
NCT04156204Phase 1Terminated
- Sponsor
- University of Colorado Denver
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tacrolimus in kidney transplant rejection, sponsored by University of Colorado Denver. Primary endpoints: Health-Related Quality of Life as assessed by change in PedsQL at Day 210, Adherence to medical therapies and medications as assessed by Medication Event Monitoring System (MEMS) at Day 210 and 3 more. Started Nov 2019; status: terminated.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04156204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156204.